Categories
Recommendation
- https://ascopubs.org/doi/10.1200/JCO-24-01798Darolutamide in Combination With Androgen-Deprivation Therapy ...Sep 16, 2024 ... PURPOSEFor patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is ...
- The New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa2119115Darolutamide and Survival in Metastatic, Hormone-Sensitive ...Feb 17, 2022 ... Studies involving patients with prostate cancer, including the phase 3 ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) ...
- https://www.cancer.gov/news-events/cancer-currents-blog/2022/darolutamide-survival-metastatic-prostate-cancerDarolutamide Extends Survival in Metastatic Prostate Cancer - NCIMar 25, 2022 ... The trio of darolutamide, ADT, and docetaxel has already been shown to improve survival in men with hormone-resistant prostate cancer that has ...
- Prostate Cancer UKhttps://prostatecanceruk.org/prostate-information-and-support/treatments/darolutamide/Darolutamide | Prostate Cancer UKDarolutamide (Nubeqa ® ) is a type of hormone therapy used to treat some men with prostate cancer. Prostate cancer cells usually need the hormone testosterone ...
- https://www.cancerresearchuk.org/about-cancer/treatment/drugs/darolutamideDarolutamide (Nubeqa) | Cancer information | Cancer Research UKJul 13, 2023 ... Darolutamide is a hormone treatment that blocks testosterone from reaching prostate cancer cells. This can slow the growth of the cancer.
- https://ascopost.com/issues/march-25-2022/triplet-combination-of-darolutamide-docetaxel-and-androgen-deprivation-therapy-extends-survival-in-metastatic-hormone-sensitive-prostate-cancer/Triplet Combination of Darolutamide, Docetaxel, and Androgen ...Mar 25, 2022 ... “These results are an important step forward for the treatment of patients with metastatic hormone-sensitive prostate cancer. Darolutamide plus ...
- U.S. Food and Drug Administrationhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancerFDA approves darolutamide for non-metastatic castration-resistant ...Jul 31, 2019 ... FDA approves darolutamide for non-metastatic castration-resistant prostate cancer ... On July 30, 2019, the Food and Drug Administration approved ...
- PubMedhttps://pubmed.ncbi.nlm.nih.gov/35179323/Darolutamide and Survival in Metastatic, Hormone-Sensitive ...Mar 24, 2022 ... In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the ...
- home-page-phase-II-newhttps://www.nubeqa-us.com/NUBEQA® (darolutamide) | Official Patient WebsiteNUBEQA® (darolutamide) is a medication for certain prostate cancers (mHSPC, nmCRPC). See safety and full prescribing info and talk to your doctor to learn ...
- PubMedhttps://pubmed.ncbi.nlm.nih.gov/30763142/Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerMar 28, 2019 ... ARAMIS Investigators ... Sergio Metrebian ... Luis Fernando Montes de Oca ... Martin Richardet ... Anthony Dowling ... Elizabeth Hovey ... Abishek Joshi ...